A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults

Completed · Phase 1

Conditions studied: Chronic Hepatitis B

In brief

This study is designed to assess the relative bioavailability of ABI-H2158 tablets (Test Formulation) compared to ABI-H2158 tablets (Reference Formulation). The effect of food on the pharmacokinetics of the Test Formulation will also be evaluated under fed and fasting conditions.

Key facts

Study ID

NCT04083716

Run by

Assembly Biosciences

People needed

15

Starts

2019-09-06

Expected to finish

2019-10-07

Last updated by the study team

2019-11-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory results at screening.

You may not qualify if…

• Positive test results for human immunodeficiency virus (HIV) or hepatitis B or C.
• Treatment for drug or alcohol dependence.

Where it is running

• Celerion — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.